We are pleased to share that our collaboration with Cambridge Cognition has been highlighted in their recent article “How do digital cognitive assessments relate to the Blood Plasma p-Tau217 in patients with Mild Cognitive Impairment (MCI)?”. The piece explores how digital cognitive assessments can be paired with blood-based biomarkers to support the early detection of Alzheimer’s disease in people with mild cognitive impairment (MCI).

Exploring p-Tau₍₂₁₇₎ and cognition

Within the AI-Mind Project, plasma p-Tau₍₂₁₇₎ has been measured in hundreds of study participants diagnosed with MCI. Elevated levels of this biomarker are known to reflect underlying Alzheimer’s pathology. By comparing biomarker results with performance on CANTAB® digital tests and traditional neuropsychological assessments, researchers found that digital tools are at least as sensitive as classical tests in identifying the cognitive changes associated with higher p-Tau₍₂₁₇₎ levels. The results were shared recently at the 2025 Alzheimer’s Association International Conference (AAIC). The poster, available under the article, offers more details about the methods and findings.

Why digital tools matter

Digital assessments provide a number of advantages over paper-based approaches. They can be:

• Remotely delivered and automatically scored,
• Scalable to large populations, and
• Efficient for clinical trials and healthcare settings.

These features align directly with AI-Mind’s mission to develop AI-based diagnostic tools for predicting dementia risk.